Market Overview

Navidea Biopharmaceuticals to Present Data on the Manocept Platform at 2018 ACR Annual Meeting

Share:

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the
"Company"), a company focused on the development of precision
immunodiagnostic agents and immunotherapeutics, announced today the
company will present a poster detailing results from the Company's
clinical trials assessing Tc 99m tilmanocept in rheumatoid arthritis
(RA) at the American College of Rheumatology (ACR) 2018 Annual Meeting,
being held October 19-24, 2018 in Chicago, Illinois. Tc 99m tilmanocept
is the first product developed and commercialized by the Company based
on the Manocept platform.

The Phase 1 and Phase 2 clinical trials enrolled subjects with active,
moderate-to-severe RA and healthy controls (HC). Images were acquired at
various time points post-injection of Tc 99m tilmanocept. Results from
the completed clinical trials show that Tc 99m tilmanocept is
well-tolerated with no drug-related adverse events observed.
Additionally, static planar images of joints in active RA subjects
demonstrated significant Tc 99m tilmanocept localization to
disease-involved joints of the shoulders, knees, hands, and feet. Whole
body and joint-specific static planar imaging in healthy control
subjects, as expected, did not reveal joint-specific localization.

Bonnie Abbruzzese, Senior Director of Clinical Research for Navidea,
said, "The ability to detect synovial macrophage activity from planar
and SPECT/CT imaging makes Tc 99m tilmanocept an immunodiagnostic agent
for the evaluation of joint-specific inflammation, characterization of
joint-level pathobiology, and individualization of treatment." Ms.
Abbruzzese continued, "The results from the completed trials support the
need for further studies to examine the correlation of tilmanocept
uptake with CD206-positive synovial macrophages over time, which may
provide valuable, clinically significant insight into the ability to
quantitatively monitor treatment response."

RA is a chronic disease affecting over 1.3 million Americans and as much
as 1% of the worldwide population.1 If the product is
successfully developed, Navidea would expect to play a major role in the
management of worldwide RA patients.

Details of Navidea's poster presentation:

Title: "Technetium Tc 99m Tilmanocept: A Targeted
Immunodiagnostic Radiopharmaceutical for the Assessment of Synovial
Macrophage Activity in Rheumatoid Arthritis" (abstract
#2211
)
Session Title: Imaging of Rheumatic Diseases
Poster III: Other Modalities
Date: Tuesday, October 23, 2018
Time:
9:00-11:00am CT

Additional information and full abstracts can be found at www.rheumatology.org

About Navidea

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) is a
biopharmaceutical company focused on the development of precision
immunodiagnostic agents and immunotherapeutics. Navidea is developing
multiple precision-targeted products based on its Manocept™ platform to
enhance patient care by identifying the sites and pathways of disease
and enable better diagnostic accuracy, clinical decision-making, and
targeted treatment. Navidea's Manocept platform is predicated on the
ability to specifically target the CD206 mannose receptor expressed on
activated macrophages. The Manocept platform serves as the molecular
backbone of Tc 99m tilmanocept, the first product developed and
commercialized by Navidea based on the platform. The development
activities of the Manocept immunotherapeutic platform are being
conducted by Navidea in conjunction with its subsidiary, Macrophage
Therapeutics, Inc. Navidea's strategy is to deliver superior growth and
shareholder return by bringing to market novel products and advancing
the Company's pipeline through global partnering and commercialization
efforts.

For more information, please visit www.navidea.com.

Reference

1. https://www.rheumatoidarthritis.org/ra/facts-and-statistics/

Forward-Looking Statements

This release and any oral statements made with respect to the
information contained in this release contains forward-looking
statements within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended. Such forward-looking statements include those relating
to the Company's participation in CAP, its growth and exposure to
industry participants, its marketing strategy, its potential for
commercial success, and ability to establish contacts with potential
collaborators, partners, and investors. We have based these
forward-looking statements largely on our current expectations and
projections about future events and financial trends affecting the
financial condition of our business. These forward-looking statements
are subject to a number of risks, uncertainties and assumptions,
including, among other things: general economic and business conditions,
both nationally and in our markets; our history of losses and
uncertainty of future profitability; the final outcome of the CRG
litigation in Texas; our ability to successfully complete research and
further development of our drug candidates; the timing, cost and
uncertainty of obtaining regulatory approvals of our drug candidates;
our ability to successfully commercialize our drug candidates; our
expectations and estimates concerning future financial performance,
financing plans and the impact of competition; our ability to raise
capital sufficient to fund our development and commercialization
programs; our ability to implement our growth strategy; anticipated
trends in our business; advances in technologies; and other risk factors
and detailed in our most recent Annual Report on Form 10-K and other SEC
filings. You are urged to carefully review and consider the disclosures
found in our SEC filings, which are available at www.sec.gov
or at http://ir.navidea.com.

Investors are urged to consider statements that include the words
"will," "may," "could," "should," "plan," "continue," "designed,"
"goal," "forecast," "future," "believe," "intend," "expect,"
"anticipate," "estimate," "project," and similar expressions, as well as
the negatives of those words or other comparable words, to be uncertain
forward-looking statements.

You are cautioned not to place undue reliance on any forward-looking
statements, any of which could turn out to be incorrect. We undertake no
obligation to update publicly or revise any forward-looking statements,
whether as a result of new information, future events or otherwise after
the date of this report. In light of these risks and uncertainties, the
forward-looking events and circumstances discussed in this report may
not occur and actual results could differ materially from those
anticipated or implied in the forward-looking statements.

View Comments and Join the Discussion!
 
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com